Get the Stockscreener App
277.16
1.16%
3.17
After Hours:
280.17
3.01
+1.09%
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $14,988,720.00 in Stock - MarketBeat
Alnylam's Crucial 2024 Financial Results Coming: Key Date for Biotech Investors - StockTitan
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Baader Bank Aktiengesellschaft Has $905,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Forsta AP Fonden Buys 3,900 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
SteelPeak Wealth LLC Has $819,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - Investing.com
Zacks Research Issues Positive Estimate for ALNY Earnings - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity - MSN
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity By Investing.com - Investing.com South Africa
New Strong Buy Stocks for January 27th - MSN
Hypertension Clinical and Non-Clinical Studies, Key - openPR
Brighton Jones LLC Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Boosted by Nisa Investment Advisors LLC - MarketBeat
Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells $3,093,750.00 in Stock - MarketBeat
Alnylam Pharmaceuticals director sharp sells $3.09 million in stock By Investing.com - Investing.com Australia
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - MSN
Alnylam Pharmaceuticals director sharp sells $3.09 million in stock - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
When the Price of (ALNY) Talks, People Listen - Stock Traders Daily
Alnylam Pharmaceuticals receives a prestigious "Tell Award" for business investment in Switzerland - StreetInsider.com
Hemophilia Clinical and Non-Clinical Studies, Key Companies, - openPR
FY2024 Earnings Estimate for ALNY Issued By Leerink Partnrs - MarketBeat
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors - BioPharma Dive
Merit Financial Group LLC Invests $587,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Traynor Capital Management Inc. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals - MSN
Perpetual Ltd Purchases 4,819 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? - MSN
Assenagon Asset Management S.A. Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Hemophilia B Market to Show Remarkable Growth Trends from 2024 - openPR
Gateway Investment Advisers LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7%Here's What Happened - MarketBeat
Empirical Asset Management LLC Takes $12.15 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
FY2024 Earnings Forecast for ALNY Issued By Zacks Research - MarketBeat
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment? - Simply Wall St
Burney Co. Buys 4,791 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
What is William Blair's Estimate for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters ATTR-CM stock outlook - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 7.1%Still a Buy? - MarketBeat
Alnylam Shares Rise 8% On Preliminary Product Revenue Growth - MarketWatch
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Alnylam shares jump on strong revenue forecast and profit outlook By Investing.com - Investing.com Australia
Alnylam shares jump on strong revenue forecast and profit outlook - Investing.com
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y (NASDAQ:ALNY) - Seeking Alpha
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
Alnylam Reports Strong 33% Growth, Sets Ambitious $2.25B Revenue Target for 2025 - StockTitan
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 -January 12, 2025 at 04:00 pm EST - Marketscreener.com
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals - MSN
Bausch + Lomb taps ex-Alnylam team's new venture for RNA eye disease programme - FirstWord Pharma
1.67%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):